What does it take to scale complex biologics manufacturing while keeping speed, quality, and communication aligned? In this episode, Ian Glassford explains how integrated CDMO partnerships are helping biotech companies accelerate ADC and bioconjugate programs from discovery through to commercial manufacturing.

This week on Making It In Manufacturing, Harry Sloan sat down with Ian Glassford, VP at Abzena, with more than a decade of experience spanning medicinal chemistry, synthetic chemistry, bioconjugation, biologics manufacturing, and CDMO leadership roles across GSK and Abzena.

In this episode, Ian Glassford covers:

• How Abzena approaches integrated ADC and bioconjugate manufacturing across discovery, development, and GMP production (00:00)

• Why communication and true partnership models are becoming critical for CDMOs supporting fast-moving biotech programs (02:55)

• The balance between speed to clinic, process standardisation, and maintaining manufacturing quality in complex biologics (03:37)

• Ian’s transition from medicinal chemistry at @GSK into leadership within the bioconjugation and ADC space at Abzena (08:11)

• Where the future of ADCs, AOCs, radionuclide conjugates, and commercial manufacturing is heading over the next five years (10:25)

For anyone working across biologics manufacturing, ADC development, CDMO partnerships, or complex therapeutics, this conversation offers a practical look at how experienced operators are adapting to increasingly demanding timelines and evolving modalities across the biotech industry.

Follow ARTO:

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng

Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr

TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1

Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575

Website: https://arto-talent.com/

Youtube: https://www.youtube.com/@artotalent

Ian Glassford:

LinkedIn: https://www.linkedin.com/in/ian-glassford-phd-mba-28270529/

Harry Sloan:

LinkedIn: https://www.linkedin.com/in/harry-sloan-605620154/?skipRedirect=true

Timestamps:

00:00 Introduction and live recording from DCAT Week in New York

00:39 Ian Glassford explains Abzena’s role in the ADC and bioconjugate CDMO market

01:25 The biggest operational challenges in ADC and AOC manufacturing

02:43 What biotech clients are really looking for beyond technical expertise

03:37 Managing the balance between speed, quality, and execution

04:53 How integrated CDMO and CRO models improve timelines and supply chain control

06:43 The importance of communication and partnership in complex programs

08:11 Ian’s career journey from medicinal chemistry into bio conjugates

10:00 Transitioning from hands-on science into site leadership

10:25 Where Abzena and the wider ADC market are heading in the next five years

11:51 Adapting CDMO models to support evolving biologics modalities

12:29 Closing thoughts

#MakingItInManufacturing #ARTOTalent #Biotech #CDMO #Biologics #ADC #DrugDevelopment #Manufacturing #Pharmaceuticals #Bioconjugates

Hosted on Acast. See acast.com/privacy for more information.

95% of our viewers aren’t subscribed. If you’re watching and not yet subscribed, please subscribe to the channel so you don’t miss future episodes.

How do leading CDMOs move beyond scale to become true strategic partners?

This week on Making It In Manufacturing, Harry Sloan sat down with John Gagliardi, Sales Director, Key Account Management at Samsung Biologics, with 25+ years of experience spanning operations, supply chain, procurement, sourcing and commercial leadership across biopharma, including previous experience at GSK and leadership in CDMO partnerships.

In this episode, John Gagliardi covers:

- How Samsung Biologics has evolved as a pure-play CDMO, including US expansion and the value of integrated support from clinical development through commercial supply.

- Why long-term partnerships in biomanufacturing depend on value creation beyond capacity, from lifecycle management to flexible supply chain strategies.

- What credible ADC capability really looks like, including integrated manufacturing, simplified supply chains and how co-located operations can accelerate speed to market.

- The strategic importance of the Lilly Gateway Labs collaboration with Eli Lilly, and how incubating early-stage biotech can strengthen the future innovation ecosystem.

- Where growth is heading next for Samsung Biologics, from Bio Campus expansion and emerging modalities to scaling quality while maintaining operational agility.

If you are interested in where biomanufacturing partnerships are heading, and how leading CDMOs are thinking beyond capacity alone, this conversation offers practical insight worth your time.

Watch the full episode to hear how John approaches growth, innovation and patient impact through a commercial and operational lens.

Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng

Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr

TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1

Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575

Website: https://arto-talent.com/

Youtube: https://www.youtube.com/@artotalent

John Gagliardi

Sales Director at Samsung Biologics

LinkedIn: https://www.linkedin.com/in/john-gagliardi-7a8a252/

Harry Sloan

CDMO BD Lead at ARTO

LinkedIn: linkedin.com/in/harry-sloan-605620154/?lipi=urn%3Ali%3Apage%3Ad_flagship3_profile_view_base%3B7ieBaX%2FATH6lSPMIPdsI8w%3D%3D

Timestamps:

00:00 Introduction from New York and conference spotlight

00:42 Samsung Biologics as a pure-play CDMO

02:10 Building strategic customer partnerships

03:45 Differentiation beyond standard CDMO models

05:01 Building credibility in ADC manufacturing

07:53 Technical collaboration and winning partnerships

09:07 Lilly Gateway Labs collaboration

11:40 Growth trajectory and future modalities

13:19 Scaling while maintaining quality

15:00 Patient impact and personal motivation

16:35 Closing remarks

#MakingItInManufacturing #ARTOTalent #Biomanufacturing #CDMO #Biopharma #SupplyChain #ADC #PharmaceuticalManufacturing #BiotechLeadership

Hosted on Acast. See acast.com/privacy for more information.

What does it really take to build credibility as a new CDMO in a highly competitive biologics market, while staying grounded in patient impact?

This week on Making It In Manufacturing, Harry Sloan sat down with Joon Chang, Chief Business Officer at Lotte Biologics, with years of experience spanning Pharma, CDMO, project management, and business development roles across global organisations.

In this episode, Joon Chang covers:

• (02:17) Building credibility as a new CDMO and overcoming the challenge of limited track record while leveraging experienced talent from legacy manufacturing sites

• (03:05) Why people and expertise matter more than company age when delivering successful tech transfer, development, and manufacturing outcomes

• (04:17) The importance of tailoring partnerships to individual client needs and building long-term relationships across Pharma and biotech organisations

• (07:00) Career journey from bench scientist to commercial leadership, and how experience across Pharma and CDMO environments shapes client-centric thinking

• (10:10) Creating a patient-centric culture in manufacturing and commercial teams, and why connecting daily operations to patient impact strengthens partnerships

If you are interested in how emerging CDMOs can differentiate themselves through culture, capability, and client alignment, this episode offers a grounded and practical perspective worth your time.

Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng

Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr

TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1

Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575

Website: https://arto-talent.com/

Youtube: https://www.youtube.com/@life_sciences

Joon Chang

LinkedIn: https://www.linkedin.com/in/joon-chang-a337895/

Harry Sloan

LinkedIn: https://www.linkedin.com/in/harry-sloan-605620154/

Timestamps:

00:00 Introduction at the DCAT Conference

00:33 Overview of Lotte Biologics and market positioning

01:20 Capabilities in biologics manufacturing and conjugation

02:01 Challenges of entering the CDMO market as a new player

03:05 Importance of talent and retained expertise from legacy sites

03:52 Building relationships with Pharma and biotech clients

04:24 Dual hub model across the US and South Korea

05:01 Manufacturing scale advantages and commercial readiness

06:19 Speed, cost efficiency, and internal tech transfer benefits

07:00 Career journey from Pharma to CDMO leadership

08:04 Understanding client mindset from both Pharma and CDMO perspectives

08:54 Project management experience and client relationship ownership

09:43 Leadership philosophy and full lifecycle thinking

10:10 Building an ideal organisational culture

10:40 Patient-centric approach and ultra-rare disease considerations

11:43 Connecting operations to patient impact

12:34 Applying culture to commercial and sales teams

13:21 Business development mission and value creation

13:40 Leadership approach and empowering teams

15:00 Vision for disrupting the CDMO industry

16:21 Growth, partnerships, and expanding patient reach

17:01 Personal motivation and purpose behind the work

18:00 Team culture and collaboration

#MakingItInManufacturing #ARTOTalent #Biologics #CDMO #Pharma #Biotech #Manufacturing

Hosted on Acast. See acast.com/privacy for more information.